Skip to main content

Cancer metabolism

Guest Editors:
Elavarasan Subramani: The University of Texas M.D. Anderson Cancer Center, United States
Marija Trajkovic-Arsic: German Cancer Consortium, Germany

BMC Cancer has published this Collection on metabolism rewiring in cancer.


Meet the Guest Editors

Back to top

Elavarasan Subramani: The University of Texas M.D. Anderson Cancer Center, United States

Dr. Subramani is a research investigator at the Department of Cancer Systems Imaging, The UT M.D. Anderson Cancer Center. He has considerable experience in metabolomics, cell, and molecular biological approaches, developing in vitro and in vivo biomarker development and drug discovery models, and defining cancer pathophysiology. He has developed and mechanistically validated robust non-invasive translatable biomarkers that can be used to identify oncogenic events associated with low-grade gliomas and that can be used to monitor response to a broad range of therapies.

Marija Trajkovic-Arsic: German Cancer Consortium, Germany

Dr. Trajkovic-Arsic obtained her Ph.D. in Endocrinology in 2008. Since 2010 she has been active in cancer research focusing on pancreatic ductal adenocarcinoma (PDAC). She is dedicated to deciphering pancreatic cancer's metabolic dependencies and further developing imaging-based approaches for reliable non-invasive detection of PDACs metabolism and its metabolic vulnerabilities. She is mostly known for her research on preclinical mouse models of PDAC and imaging technologies used for addressing PDACs heterogeneity, microenvironment complexity, metabolic activity, and therapy development and evaluation. 

About the collection

BMC Cancer has published this Collection on metabolism rewiring in cancer.

The first observations on metabolic alterations in cancer were made nearly a century ago by Otto Warburg, who discovered the metabolic differences between lactate production of cancer cells and non-malignant tissues. It is now well known that metabolic perturbations are a hallmark of cancer, which allows cancer cells to sustain their uncontrolled proliferation even in a frequently nutrient-poor environment. In the past decade, the field of cancer metabolism has become a topic of renewed interest, unrevealing the impact of metabolic rewiring in the cancer-microenvironment crosstalk and the onset of therapeutic resistance and metastasis.

In recognition of this important field, BMC Cancer has published this Collection which encouraged submissions including but not limited to those addressing:

• Genetic alterations involved in the metabolic reprogramming 

• Metabolic alterations within the microenvironment 

• Therapeutic approaches targeting cancer metabolism at the cellular or organismal levels 

• Metabolites as tumor biomarkers

• Tumor metabolism as a diagnostic tool

• Tumor metabolism and therapy response imaging technologies

• Redox homeostasis in cancer metabolism

• Cancer metabolomics and multi-omics data integration

• Sex-specific metabolic alterations in cancers

• Improving in vitro cancer metabolism studies (new media formulations/conditions)

Image credit: © nobeastsofierce / Stock.adobe.com

  1. Understanding the metabolic changes in colorectal cancer (CRC) and exploring potential diagnostic biomarkers is crucial for elucidating its pathogenesis and reducing mortality. Cancer cells are typically deriv...

    Authors: Xuancheng Wang, Xuan Guan, Ying Tong, Yunxiao Liang, Zongsheng Huang, Mingsen Wen, Jichu Luo, Hongwei Chen, Shanyi Yang, Zhiyong She, Zhijuan Wei, Yun Zhou, Yali Qi, Pingchuan Zhu, Yanying Nong and Qisong Zhang
    Citation: BMC Cancer 2024 24:644
  2. Meningiomas are among the most common primary tumors of the central nervous system. Previous research into the meningioma histological appearance, genetic markers, transcriptome and epigenetic landscape has re...

    Authors: D. Orešković, A. Madero Pohlen, I. Cvitković, J.F. Alen, M. Raguž, A. Álvarez-Sala de la Cuadra, G.J. Bazarra Castro, Z. Bušić, I. Konstantinović, V. Ledenko, C. Martínez Macho, D. Müller, M. Žarak, N. Jovanov-Milosevic, D. Chudy and T. Marinović
    Citation: BMC Cancer 2024 24:488
  3. Clear cell renal cell carcinoma (ccRCC) is the prevailing histological subtype of renal cell carcinoma and has unique metabolic reprogramming during its occurrence and development. Cell senescence is one of th...

    Authors: Lijie Zhou, Youmiao Zeng, Yuanhao Liu, Kaixuan Du, Yongbo Luo, Yiheng Dai, Wenbang Pan, Lailai Zhang, Lei Zhang, Fengyan Tian and Chaohui Gu
    Citation: BMC Cancer 2024 24:451
  4. T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a cell surface molecule that was first discovered on T cells. However, recent studies revealed that it is also highly expressed in acute myeloid l...

    Authors: Hooriyeh Shapourian, Mustafa Ghanadian, Nahid Eskandari, Abolfazl Shokouhi, Gülderen Yanikkaya Demirel, Alexandr V. Bazhin and Mazdak Ganjalikhani-Hakemi
    Citation: BMC Cancer 2024 24:125
  5. Prostate cancer is a common solid tumor that affects a significant number of men worldwide. Conventional androgen deprivation therapy (ADT) increases the risk of developing castration-resistant prostate cancer...

    Authors: Xingchen Dai, Xinyi Shi, Mingxiu Luo, Pu Li and Yujing Gao
    Citation: BMC Cancer 2023 23:1241
  6. Glioblastoma patients commonly develop resistance to temozolomide chemotherapy. Hypoxia, which supports chemotherapy resistance, favors the expansion of glioblastoma stem cells (GSC), contributing to tumor rel...

    Authors: Nadia Sousa, Carsten Geiß, Laura Bindila, Ingo Lieberwirth, Ella Kim and Anne Régnier-Vigouroux
    Citation: BMC Cancer 2023 23:762
  7. Altered cellular metabolism has long been recognized as a hallmark of cancer. Oncogenic signaling cascades induce metabolic rewiring that further supports tumorigenesis, therapy resistance and metastasis. In v...

    Authors: Marija Trajkovic-Arsic and Elavarasan Subramani
    Citation: BMC Cancer 2023 23:484

Submission Guidelines

Back to top

This Collection welcomes the submission of Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cancer metabolism" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.